Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13C-Methacetin Breath Test in Acute Liver Injury or Acute Liver Failure
NCT02786836Phase 3Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 13C-methacetin in acute liver failure (ALF) and acute liver injury (ALI), sponsored by UT Southwestern Medical Center. Primary endpoint: Peak Percent Dose Recovery at Day 21. Started Jun 2016; status: completed.
02
Drugs
13C-methacetin
03
Conditions
acute liver failure (ALF)acute liver injury (ALI)
Beyond the preview
Go deeper on NCT02786836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786836.